Last deal

$2.54M
Local Amount - GBP 2M

Amount

Post-IPO Debt

Stage

03.08.2023

Date

2

all rounds

$3.81M

Total amount

date founded

Financing round

General

About Company
Sareum develops targeted therapeutics for cancer and autoimmune diseases, aiming to license them to pharmaceutical companies.

Industry

Sector :

Subsector :

Also Known As

Sareum Holdings

founded date

01.01.2003

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Debt

IPO status

Private

Description

The company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase, and Tyrosine Kinase 2- autoimmune diseases (TYK2), with its Chk1 program being the most advanced and showing potency in disease models of lung and colon cancers in combination with chemotherapy, acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. Sareum is also advancing internal programs focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases and cancer immunotherapy.
Contacts
Similar Companies
1000
Arrien Pharmaceuticals

Arrien Pharmaceuticals

Arrien Pharmaceuticals is a drug discovery and development company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Ansonia, CT, USA

total rounds

1

total raised

$2M
Abbisko Therapeutics

Abbisko Therapeutics

Abbisko Therapeutics develops small molecule drugs for cancer and other diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Shanghai, China

total rounds

4

total raised

$263M
Idera Pharmaceuticals

Idera Pharmaceuticals

Idera Pharmaceuticals develops DNA- and RNA-based drugs for various diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Cambridge, MA, USA

total rounds

4

total raised

$74.5M
Ascentage Pharma

Ascentage Pharma

Ascentage Pharma is a global biotechnology company developing novel therapies for cancers, hepatitis B, and age-related diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Suzhou, Jiangsu, China

total rounds

4

total raised

$312.49M

count Of Investments

1

Financials

Funding Rounds
2
2

Number of Funding Rounds

$3.81M

Money Raised

Their latest funding was raised on 03.08.2023. Their latest investor Riverfort Global Opportunities. Their latest round Post-IPO Debt

Date 
Funding Round 
Investors 
Money Raised 
Lead 
03.08.2023
1
$2.54M
Local Amount - GBP 2M
03.06.2021
$1.27M
Local Amount - GBP 900K
Riverfort Global Opportunities

Riverfort Global Opportunities

Riverfort Global Opportunities is an investment company that focuses on investing in natural resources, technology, and healthcare sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Finance, Venture Capital

Location

London, UK

count Of Investments

7

count Of Exists

1
Co-Investors
Investors
1
1

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
Riverfort Global Opportunities

Riverfort Global Opportunities

Riverfort Global Opportunities is an investment company that focuses on investing in natural resources, technology, and healthcare sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Finance, Venture Capital

Location

London, UK

count Of Investments

7

count Of Exists

1

People

Founders
2
Tim Mitchell
Tim Mitchell

Tim Mitchell

Tim is a twelve-year veteran in the ongoing convergence of technology and digital media. He began his career on the web, literally where it all began – at Wired Magazine’s “Hotwired”, the first ad-supported content portal and also pre-Google search innovator, HotBot. He went on to hold lead product management and director roles at Lycos, Terra, and CNET, where he focused on digital music, streaming video, and media software. After building his chops at larger media companies, Tim waded into the start-up world, where he held multiple executive roles at IODA, a leading digital distribution and marketing company for independent record labels. He’s been quoted in Red Herring, Billboard, Digital Music News, Wired.com, and Villagevoice.com; and he has spoken on panels at NARM, Winter Music Conference, CMJ, Digital Hollywood, and more. Tim graduated from California Polytechnic State University, San Luis Obispo with a BA in Economics. Outside of the office, Tim spends most of his time on his bike or on stage with his band.

current job

Sareum Holdings PLC
Sareum Holdings PLC

organization founded

1

Tim Mitchell

David Williams
David Williams

David Williams

David Williams is the chief executive officer at Nanna Therapeutics. David has been working in the pharmaceutical industry for over 30 years, passionately and directly involved in all aspects of drug discovery and development working towards providing treatments for many diseases including new drugs marketed for infectious disease and cancer. Originally in banking, he retrained as a scientist going on to develop distinguished expertise in signal transduction and structural biology research, having authored or co-authored over 70 significant publications and patents. As well as co-founding the successful antibiotics company, Discuva, in 2009, David co-founded the disruptive therapeutics company, Bactevo; the AIM-listed oncology drug discovery company Sareum; and as part of senior management steered Summit PLC back to financial and scientific viability. Other major roles in UK/US senior management and research were performed at Millennium Pharmaceuticals, Medivir, Acambis and Roche.

current job

Nanna Therapeutics
Nanna Therapeutics

David Williams

Employee Profiles
4
Stephen Parker

Stephen Parker

Chairman

Tim Mitchell

Tim Mitchell

Founder & CEO

Activity

Recent News
2
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range